Claritas to Collaborate with Salzman Group and Other Companies to Accelerate Development of R-107 for Treatment of Vaccine-Resistant Covid-19, Influenza, and Other Viral Infections
March 03, 2021 at 08:30 am EST
Share
Claritas Pharmaceuticals, Inc. announced that it has entered into a Strategic Collaboration Agreement with the Salzman Group Ltd. and is in the process of entering into similar agreements with other companies, to expedite the development of the Company’s breakthrough nitric oxide-releasing compound, R-107. To conserve capital and expedite the development of R-107, Claritas is collaborating with the Salzman Group and other companies for the manufacture of R-107, and for the design and completion of clinical studies to demonstrate the safety and efficacy of R-107 in the treatment of COVID-19, influenza, and other viral infections. Under the Collaboration Agreement, Salzman Group will make available to Claritas the full capabilities of Salzman Group, including its expertise in working with nitric oxide and nitric oxide releasing compounds. Salzman Group will also provide a platform of services, including expertise in the manufacture of R-107, design of clinical studies, and consulting services in connection with Claritas’ interactions with regulatory bodies in the USA, Australia, the UK, and the EU.
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Companyâs products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.
Claritas to Collaborate with Salzman Group and Other Companies to Accelerate Development of R-107 for Treatment of Vaccine-Resistant Covid-19, Influenza, and Other Viral Infections